United States· US:0078-1049_2e07448f-f888-4747-80ab-570c1b621250
Lamprene
A clofazimine product containing clofazimine, registered in United States by Novartis Pharmaceuticals Corporation. The same ATC class is registered in 7 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Clofazimine is registered in 7 of 19 countries.
Countries holding a registration under ATC J04BA01 (clofazimine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 5 of them publish a price we can compare per daily dose
Clofazimine · ATC J04BA01
7 / 19 countries
- Czechiaprice
- Franceprice
- Japan
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CLOFAZIMINE
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Country
- United States (US)
- ATC code
- J04BA01
- ATC class
- Clofazimine
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 16, 2026
Packs & prices · 1
- ndc110078-1049-05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
158 interactions on record for clofazimine.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Clofazimine · interactions on record
158 records
- 37 severe
- 119 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Clofazimine in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLAMPRENE
- FranceLAMPRENE 50 mg, capsule molleNOVARTIS PHARMA
- NorwayLampreneNovartis
- United KingdomClofazimine 100mg capsulesSpecial Order
- SpainLAMPREN CAPSULASNovartis Farmaceutica S.A.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- France · Lamprene
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b9561eb7-93f8-4a9e-aa73-162b7c162e9a GET /v1/drugs/b9561eb7-93f8-4a9e-aa73-162b7c162e9a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "50",
"substance": "CLOFAZIMINE",
"productndc": "0078-1049",
"dosage_form": "CAPSULE, LIQUID FILLED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA019500",
"marketing_category": "NDA"
}See everything about clofazimine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.